Mdxhealth SA revenue by segment MDXH
Annual
Quarterly
Mdxhealth SA splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Tissuebased Revenue at $81.5 million, 76% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|
| Revenue |
108
|
90
|
70
|
37
|
22
|
| Tissuebased Revenue |
81
+12.7%
share 75.5%
|
72
+29.8%
share 80.3%
|
56
share 79.4%
|
—
|
—
|
| Liquidbased Revenue |
26
+48.2%
share 24.2%
|
18
+23.4%
share 19.5%
|
14
share 20.3%
|
—
|
—
|
| Royalties And Other Revenues |
0
+134.5%
share 0.3%
|
0
-39.0%
share 0.2%
|
0
share 0.3%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- MDXH (Nasdaq)
- Incorporated in
- Belgium
- Headquarters
- Herstal, Belgium
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1872529
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.